Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 3/20 | 0.65 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.65 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.65 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.65 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.65 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.65 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.65 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.65 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.65 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17599105 | 0.90 | CYP1A1 (0.71) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL26710974 | 0.86 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL10137021 | 0.86 | ACHE (0.58) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL1045967 | 0.85 | ACHE (0.52) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL2096959 | 0.83 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL10169411 | 0.83 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL7218648 | 0.83 | CYP3A4 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL8563139 | 0.83 | CYP1A1 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL7143439 | 0.83 | CYP3A4 (0.62) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL5632975 | 0.82 | CYP1A1 (0.79) | CYP1A1CYP1B1CYP1A2CYP2E1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMA CO LTD (JP) | 2015-08-13 | — | — | US | disclosed |
| US-8987304-B2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-03-24 | — | — | US | disclosed |
| US-8791104-B2 | 1,4-benzodiazepine-2,5-diones with therapeutic properties | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-10-03 | — | — | US | disclosed |
| EP-2269694-A2 | Antituberculous composition comprising oxazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-01-05 | — | — | EP | disclosed |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-11-05 | — | — | US | disclosed |
| EP-1465900-B1 | RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224099-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A1 276/4885CYP1B1 201/4885CYP1A2 135/4885 |
| US-20090275528-A1 | ANTITUBERCULOUS COMPOSITION COMPRISING OXAZOLE COMPOUNDS | OXA1L, ARG1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CYP1A1 276/4885CYP1B1 201/4885CYP1A2 135/4885 |
| US-20130261110-A1 | NOVEL 1,4-BENZODIAZEPINE-2,5-DIONES WITH THERAPEUTIC PROPERTIES | BAD, GABRA5, GABRB1 | CYP1A1 996/4885CYP1B1 384/4885CYP1A2 755/4885 |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | CYP1A1 3058/4885CYP1B1 1761/4885CYP1A2 1879/4885 |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | CIT, PTGIS, PTGIR | CYP1A1 2516/4885CYP1B1 1495/4885CYP1A2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.